
The basis of allotment for the ₹1,824.12 crore Central Mine Planning & Design Institute IPO will be announced today, 25 March 2026. The bidding window was open from March 20, 2026, to March 24, 2026, during which the IPO received a subscription of 1.05x
The Central Mine Planning & Design Institute IPO is a book-building issue of ₹1,824.12 crore, comprising an entirely offer-for-sale of 10.71 crore shares. The price band is set between ₹163 and ₹172 per share.
The book-running lead managers for the IPO are IDBI Capital Markets & Securities Limited and SBI Capital Markets Limited, while KFin Technologies Limited is the registrar for the issue.
As the issue is entirely an offer for sale, the company will not receive any proceeds from the offer; all proceeds will be received by the promoter selling shareholder.
Explore other Upcoming IPOs on BSE and NSE.
[11-March-2026 18:24:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
2.51 |
|
Non-Institutional Investors |
2.59 |
|
Retail Individual Investors (RIIs) |
0.27 |
|
Total |
1.12 |
According to media reports, the Grey Market Premium (GMP) for the Central Mine Planning & Design Institute IPO is ₹7 over the IPO price.
Central Mine Planning & Design Institute (CMPDI) provides end-to-end consultancy and technical support services across the full value chain of coal and mineral exploration, mine planning, and project design.
Their service offerings cover every stage of a mining project, from early-stage exploration and resource assessment to mine development, operations optimisation, and eventual closure planning.
CMPDI was accorded “Mini Ratna” status (Category II) in 2009 and later upgraded to Category I in 2019. Their service portfolio extends beyond core mining activities to include infrastructure engineering, environmental solutions, geomatics, advanced technology integration, and management systems.
Check out newly Listed IPOs on BSE and NSE.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.